CCT369260 is an orally active, B-cell lymphoma 6 (BCL6) inhibitor with antitumor activity and an IC50 value of 520 nM.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 200 mg/mL|
|Related Bcl-2 Products|
BI-3802 is a potent degradation of oncogenic transcription factor BCL6 with strong inhibitory effect on target genes and anti-proliferative effect.BI-3802 inhibits the BTB structural domain of BCL6, corresponding to an IC50 value ≤ 3 nM.BI-3802 has anti-tumor activity.
BCL-2 inhibitor prodrug (ABBV-167) is a phosphate prodrug of venetoclax with the potential ability to study chronic lymphocytic leukemia (CLL).
Obatoclax (GX15-070) is an antagonist of Bcl-2 with an Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis.
BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM.
WEHI-539 hydrochloride is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.